Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials
Table 1
Baseline characteristics of patient treated in both clinical trials.
All ()
Spanish trial ()
Brazilian trial ()
Age
0.03
Gender (male)
15 (68.2%)
5 (50%)
10 (83.3%)
0.17
Hypertension
15 (68.2%)
6 (60%)
9 (75%)
0.62
Diabetes
9 (40.9%)
3 (30%)
6 (50%)
0.41
Dyslipidemia
9 (40.9%)
4 (40%)
4 (33.3%)
0.99
Tobacco
5 (22.7%)
1 (10%)
4 (33.3%)
0.32
Cardiopathy
2 (9.1%)
0 (0%)
2 (16.7%)
0.48
AF
4 (18.2%)
2 (20%)
2 (16.7%)
0.99
TOAST
LAA
3 (13.6%)
0 (0%)
3 (25%)
0.39
CE
9 (40.9%)
4 (40%)
5 (41.7%)
LAC
1 (4.5%)
1 (10%)
0 (0%)
UND
7 (31.8%)
4 (40%)
3 (25%)
OTH
2 (9.1%)
1 (10%)
1 (8.3%)
Side
Right
9 (40.9%)
4 (40%)
5 (41.7%)
0.99
Left
13 (59.1%)
6 (60%)
7 (58.3%)
VB
—
—
—
IV thrombolysis
7 (31.8%)
4 (40%)
3 (25%)
0.65
IA therapy
1 (4.5%)
0 (0%)
1 (8.3%)
0.99
NIHSS (baseline)
13.0 [9.7–16.0]
15.5 [10.7–18.0]
11.5 [9.0–14.5]
0.07
Infarct volume#
0.22
Injection days
<0.001
Number of cells
153.5 (100–320)
138.5 (76–210)
223.5 (128–395)
0.20
Values are expressed as means ± SD. ; #. BM-MNC indicates bone marrow mononuclear cell.
